PMID- 33310272
OWN - NLM
STAT- MEDLINE
DCOM- 20210514
LR  - 20210514
IS  - 1873-3557 (Electronic)
IS  - 1386-1425 (Linking)
VI  - 248
DP  - 2021 Mar 5
TI  - Flourimetric study on antidiabetic combined drugs; empagliflozin and linagliptin 
      in their pharmaceutical formulation and human plasma.
PG  - 119258
LID - S1386-1425(20)31237-3 [pii]
LID - 10.1016/j.saa.2020.119258 [doi]
AB  - Empagliflozin and linagliptin are newly approved FDA combination that used for 
      the treatment of type 2 diabetes mellitus (T2DM) under trade name Glxambi. Two 
      spectroflourimetric methods were developed for simple quantitative determination 
      of empagliflozin and linagliptin in their pharmaceutical formulation and human 
      plasma without need any tedious processing operations. Empagliflozin has a native 
      fluorescence nature, therefore can be directly determined by measuring emission 
      peak at 305 nm after excitation at 234 nm. There is no any interference from 
      linagliptin at this emission wavelength. On the other hand, linagliptin is a very 
      weak florescent compound that needs to react with fluorogenic reagent to be 
      quantitatively determined without any reaction of empagliflozin. So, quantitative 
      analysis of linagliptin was achieved by coupling with NBD-Cl which is an electro 
      active halide reagent (targeting only Linagliptin with no effect on 
      empagliflozin). Dark yellow fluorophore with high fluorescence is a result of 
      this reaction and can be measured at emission wavelength 538 nm after excition at 
      wavelength 469 nm. Experimental conditions of the suggested methods were well 
      checked and optimized. The regression plots were found to be linear over the 
      range of 40-1200 ng/mL and 3-700 ng/mL for empagliflozin and linagliptin, 
      respectively. The obtained results by the suggested methods were statistically 
      compared with those obtained by the reported methods, showing no significant 
      difference with respect to accuracy and precision at p = 0.05.
CI  - Copyright (c) 2020 Elsevier B.V. All rights reserved.
FAU - Elmasry, Manal S
AU  - Elmasry MS
AD  - Analytical Chemistry Department, Faculty of Pharmacy, Zagazig University, Zagazig 
      44519, Egypt. Electronic address: ms.elmasry@yahoo.com.
FAU - Hasan, Mohamed A
AU  - Hasan MA
AD  - Pharmaceutical Analytical Chemistry Department, Faculty of Pharmacy, Al-Azhar 
      University, Nasr City, Cairo 11751, Egypt.
FAU - Hassan, Wafaa S
AU  - Hassan WS
AD  - Analytical Chemistry Department, Faculty of Pharmacy, Zagazig University, Zagazig 
      44519, Egypt.
FAU - Merey, Hanan A
AU  - Merey HA
AD  - Analytical Chemistry Department, Faculty of Pharmacy, Cairo University, 
      Kasr-El-Aini, Cairo 11562, Egypt; Analytical Chemistry Department, Faculty of 
      Pharmacy, October 6 University, 6 October City, Giza 12585, Egypt.
FAU - Nour, Israa M
AU  - Nour IM
AD  - Pharmaceutical Chemistry Department, Faculty of Pharmacy, Egyptian Russian 
      University, Badr 11829, Egypt.
LA  - eng
PT  - Journal Article
DEP - 20201130
PL  - England
TA  - Spectrochim Acta A Mol Biomol Spectrosc
JT  - Spectrochimica acta. Part A, Molecular and biomolecular spectroscopy
JID - 9602533
RN  - 0 (Benzhydryl Compounds)
RN  - 0 (Dipeptidyl-Peptidase IV Inhibitors)
RN  - 0 (Glucosides)
RN  - 0 (Hypoglycemic Agents)
RN  - 3X29ZEJ4R2 (Linagliptin)
RN  - HDC1R2M35U (empagliflozin)
SB  - IM
MH  - Benzhydryl Compounds
MH  - *Diabetes Mellitus, Type 2/drug therapy
MH  - *Dipeptidyl-Peptidase IV Inhibitors
MH  - Drug Compounding
MH  - Glucosides
MH  - Humans
MH  - Hypoglycemic Agents
MH  - Linagliptin
OTO - NOTNLM
OT  - Empagliflozin
OT  - Linagliptin
OT  - NBD-Cl
OT  - Spectroflourimetry
COIS- Declaration of Competing Interest The authors declare that they have no known 
      competing financial interests or personal relationships that could have appeared 
      to influence the work reported in this paper.
EDAT- 2020/12/15 06:00
MHDA- 2021/05/15 06:00
CRDT- 2020/12/14 10:27
PHST- 2020/10/19 00:00 [received]
PHST- 2020/11/20 00:00 [revised]
PHST- 2020/11/25 00:00 [accepted]
PHST- 2020/12/15 06:00 [pubmed]
PHST- 2021/05/15 06:00 [medline]
PHST- 2020/12/14 10:27 [entrez]
AID - S1386-1425(20)31237-3 [pii]
AID - 10.1016/j.saa.2020.119258 [doi]
PST - ppublish
SO  - Spectrochim Acta A Mol Biomol Spectrosc. 2021 Mar 5;248:119258. doi: 
      10.1016/j.saa.2020.119258. Epub 2020 Nov 30.